U.S. Stock Market Midday Update
Kodiak Sciences fell 11.93%, with increased trading volume. According to recent key news:
<ol>
<li>
On September 22, Jefferies announced a target price of $15 per share for Kodiak Sciences and gave it a buy rating. This news initially boosted the stock price, but the market's mixed reaction led to price fluctuations.
</li>
<li>
On September 23, Kodiak Sciences' dual antibody KSI-501 entered Phase III trials, and the market held a wait-and-see attitude towards its prospects, resulting in a stock price decline.
</li>
<li>
On September 23, MarketBeat reported that top analysts believe five stocks are more worthy of investment than Kodiak Sciences, further undermining market confidence and causing the stock price to drop. The biotechnology sector has been volatile recently, requiring cautious attention.
</li>
</ol>
Top Stocks by Trading Volume in the Industry
Regeneron Pharmaceuticals fell 4.52%, with a trading volume of $343 million, showing increased activity. Based on recent key news:
<ol>
<li>
On September 22, the European Medicines Agency's Committee for Medicinal Products for Human Use gave a positive opinion on Dupixent for the treatment of chronic spontaneous urticaria, advancing the drug's approval process in the EU. This news positively impacted Regeneron Pharmaceuticals' stock price, but the market's mixed reaction led to price fluctuations.
</li>
<li>
On September 22, market analysts maintained a &#34;moderate buy&#34; rating for Regeneron Pharmaceuticals, with an average target price of $739.95, suggesting a 24.22% upside potential. However, some top analysts believe other stocks offer better investment value, which has affected market confidence in Regeneron Pharmaceuticals.
</li>
<li>
On September 22, a press release from Regeneron Pharmaceuticals mentioned that Dupixent showed significant reductions in itching and urticaria over 24 weeks in two trials, supporting the drug's positive opinion, but uncertainty remains regarding future approval outcomes. The healthcare sector has shown volatility recently, necessitating attention to policy changes.
</li>
</ol>
Gilead Sciences rose 0.99%. Based on recent important news:
<ol>
<li>
On September 22, Ensoma announced it secured $53 million in funding to support key clinical milestones for EN-374 and the ongoing development of its in vivo hematopoietic stem cell engineering pipeline. Gilead Sciences, as one of the investors, appointed an executive to Ensoma's board, enhancing market confidence in Gilead Sciences and driving the stock price up.
</li>
<li>
On September 21, market analysts rated Gilead Sciences as a moderate buy but noted that five stocks are more valuable investments. Nevertheless, Gilead Sciences' solid performance continues to attract investor attention.
</li>
<li>
On September 23, competition in the industry’s technological pathways intensified, and Gilead Sciences needs to choose strategies cautiously in a tightening capital environment to avoid blindly chasing trends. In this context, investors' assessments of its technological potential have influenced stock price fluctuations
The competition in the biotechnology industry is intensifying, requiring caution.
</li>
</ol>
AbbVie rose by 0.15%. Based on recent important news:
<ol>
<li>
On September 23, AbbVie's Allergan Aesthetics announced the expansion of Skinvive by Juvederm into 35 new markets, reinforcing its commitment to global skin quality enhancement. This expansion plan may drive the company's growth in the beauty market and boost investor confidence. Source: Company press release.
</li>
<li>
On September 23, AbbVie was named a Dividend King, having increased its dividend for 53 consecutive years, with a forward yield of 3%, significantly higher than the S&amp;P 500 average. This demonstrates the company's attractiveness for long-term investment. Source: Analyst report.
</li>
<li>
On September 22, market analysts rated AbbVie's stock as a moderate buy but did not list it as one of the top recommended stocks. This may affect investors' expectations for its short-term performance. Source: Market analysis report. Expansion in the beauty market and high dividend attractiveness.
</li>
</ol>
Stocks ranked among the top in industry market capitalization
Amgen fell by 0.20%, with increased trading volume. According to recent key news:
<ol>
<li>
On September 23, Amgen's stock price slightly declined, with analysts maintaining a &#34;hold&#34; rating, believing that other stocks are more attractive, leading to insufficient investor confidence and pressure on the stock price. Source: MarketBeat.
</li>
<li>
On September 22, after the Federal Reserve cut interest rates, the market's optimism about the economic outlook failed to boost Amgen's stock price, as it was not included in the analysts' recommended buy list. Source: MarketBeat.
</li>
<li>
On September 21, market analysts pointed out that although Amgen holds a significant position in the biopharmaceutical field, in the current market environment, investors are more inclined to choose other stocks with greater growth potential. Source: MarketBeat. The biopharmaceutical industry is facing competitive pressure
</li>
</ol>

Kodiak Sciences fell 11.93%; Regeneron Pharmaceuticals fell 4.52%, with a trading volume of USD 343 million; Gilead Sciences rose 0.99%, with a trading volume of USD 329 million; AbbVie rose 0.15%, with a trading volume of USD 323 million; Amgen fell 0.20%, with a market capitalization of USD 153.7 billion

U.S. Stock Market Update: Kodiak Sciences down 11.93%